Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
Recruiting
Phase 2
Interventional Study
Pulmonary Fibrosis
Lung Fibrosis
Idiopathic Pulmonary Fibrosis
FAP
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 70 (estimated)
- Sponsor
- Erasme University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults patients with a fibrotic lung disease (idiopathic pulmonary fibrosis (IPF) or non-IPF fibrotic ILD) as defined according to the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guidelines
Exclusion Criteria:
* Pregnant or nursing patients
* Patients with another significant me…
Contacts